Kyoto University · Medicine
Professor Masayuki Ueno's research lab focuses on gastrointestinal oncology, with a primary emphasis on rectal cancer management, immune-related adverse events from cancer immunotherapy, and the pathogenesis of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. The lab investigates risk factors for metastasis, such as lateral lymph node involvement in advanced rectal cancer, and explores treatment responses and complications related to immune checkpoint inhibitors, including severe pancreatitis. Additionally, the lab contributes to understanding metabolic liver disease and optimizing treatment strategies for hepatocellular carcinoma, particularly in the context of systemic therapy and stereotactic body radiation therapy. These efforts reflect a translational approach integrating clinical oncology, hepatology, and immunology to improve patient outcomes.
Figures are computed from collected data and may differ slightly.
Abstract Background Lateral lymph node metastases occur in some patients with low rectal cancer and may cause local recurrence after total mesorectal excision. The aims of this study were to identify risk factors for lateral node metastases in patients with pathological tumour (pT) stage 3 or pT4 low rectal adenocarcinoma, and to evaluate the prognostic significance of lateral node metastases. Methods A retrospective analysis was performed of the outcome of 237 patients with pT3 or pT4 low recta
We herein report a case of fatal pancreatitis induced by an immune checkpoint inhibitor. A 62-year-old man with cancer of unknown primary was treated with pembrolizumab. After 12 cycles, immune-related pneumonitis developed and was treated with prednisolone. Three months later, pancreatitis developed, which was successfully treated with hydration and protease inhibitors. Eight months later, another attack of pancreatitis occurred, which did not respond to therapy, including high-dose corticoster
High rates of excessive calorie intake diets and sedentary lifestyles have led to a global increase in nonalcoholic fatty liver disease (NAFLD). As a result, this condition has recently become one of the leading causes of hepatocellular carcinoma (HCC). Furthermore, the incidence of NAFLD-associated HCC (NAFLD-HCC) is expected to increase in the near future. Advanced liver fibrosis is the most common risk factor for NAFLD-HCC. However, up to 50% of NAFLD-HCC cases develop without underlying live
MMF appears to be an appropriate treatment option for ICI-related liver injury that respond to high-dose corticosteroids but relapse during steroid tapering.
SBRT had modestly negative impact on liver function but with appraisable local control of HCC. Our findings should contribute to the selection of this modality for treatment of single, small HCC.
Approximately one-third of patients were refractory to first-line Atezo/Bev therapy. The CRAFITY score demonstrated superior performance in predicting refractoriness.
In this real-world study, only 26.2% of patients received third-line chemotherapy. Poor performance status and high serum C-reactive protein value at the start of first-line chemotherapy were significantly associated with lower frequency of administration of third-line chemotherapy.
A few decades ago, antibiotic prophylaxis for patients with acute variceal bleeding was reported beneficial. However, endoscopic and systemic therapy for variceal bleeding has dramatically improved since then, so the necessity of prophylactic antibiotics can be questioned. In this study, we reevaluated the efficacy of antibiotic prophylaxis in acute variceal bleeding, using the most recent data in our hospital.We retrospectively analyzed the medical records of 150 patients with acute variceal bl
The number of AYA-CRC cases is increasing in Japan. Before initiating treatment for AYA-CRC, we should know that these patients may have a hereditary disease and fertility preservation should be explained. More physicians should be aware of the importance of AYA-CRC.
結腸癌他臓器合併切除例について, 臨床病理学事項および治療成績について検討した。当科にて手術した単発結腸癌治癒切除783例のうち, 他臓器合併切除例は90例 (11.5%) を占める。これらの原発部位は, 右結腸曲を筆頭に右側結腸が高頻度で, 腫瘍は大型, 全周性で, 組織型では粘液癌の頻度が高く, 切除臓器は小腸腹壁, 膀胱などが多かった.組織学的他臓器浸潤 (si) 症例は36例 (40%) に認め, 癌浸潤の肉眼診断との一致率は72%であった。切除後5年生存率は合併切除全例64.5%, si例62.5%であり, 膵頭十三指腸切除例でも7例中4例に長期生存を認めた.再発形式は腹膜および局所再発が半数を占めた.小腸浸潤例では, 小腸粘膜まで浸潤した3例において, 小腸間膜への二次的リンパ節転移を認めた.以上結腸癌の他臓器浸潤の肉眼診断は困難であるが, 浸潤を疑う場合は, 浸潤臓器のリンパ節を含む合併切除が必要であると考えられた.
Pulse steroid therapy can cause DI-ALH, especially when subsequent prednisolone is not tapered. Prednisolone is effective for DI-ALH due to pulse steroid therapy, and can be safely withdrawn once remission is achieved.
Open papers in the app to read, cite, and organize with AI.
